Peer-reviewed veterinary case report
Neurological side effects of isoxazoline flea treatments in cats
By Bates, Nicola et al.·Published in The Veterinary record·2024·Veterinary Poisons Information Service, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Neurological adverse effects of isoxazoline exposure in cats and dogs.
Plain-English summary
A group of cats and dogs experienced muscle tremors and convulsions after being exposed to isoxazolines, a type of flea and tick medication. In dogs, these neurological signs appeared after both regular doses and overdoses, while in cats, they mostly occurred after using topical treatments. Fortunately, all the pets that had follow-up information recovered after experiencing these symptoms. It's important for pet owners to be aware of these potential side effects when using isoxazolines.
People also search for: dog muscle tremors after flea treatment · cat convulsions from isoxazolines · isoxazoline side effects in pets
Abstract
BACKGROUND: Isoxazolines are rarely reported to be associated with neurological adverse events in cats and dogs, but information about the onset and duration of neurological signs is lacking in the summary of product characteristics of these medicines. METHODS: The Veterinary Poisons Information Service and the Dutch Poisons Information Center databases were searched using the Veterinary Dictionary for Drug-Related Affairs terms for ataxia, muscle tremor, convulsions or hyperesthesia in cats and dogs exposed to isoxazolines. RESULTS: There were 22 cases with and 57 cases without outcome information, mostly involving fluralaner or sarolaner. In both groups, muscle tremors and convulsions were the most common signs. In dogs, neurological signs occurred with oral therapeutic dose and overdosage. In cats, most fluralaner cases involved therapeutic topical exposure, and all sarolaner cases involved oral exposure. In all cases with outcome information, the animals recovered. LIMITATIONS: Cases discussed with poison centres tend to involve more severe signs. CONCLUSION: The true incidence of neurological adverse effects from isoxazolines remains unclear. The delay between the administration and onset of signs can be long, and the association may be missed. A lack of timing information in the summary of product characteristics could also contribute to missed attribution of adverse effects.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38616548/